Patents Represented by Attorney, Agent or Law Firm Heska Corporation
  • Patent number: 7438919
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: October 21, 2008
    Assignee: The University of Pittsburgh -- of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7399477
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: July 15, 2008
    Assignee: The University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7195767
    Abstract: The present invention includes a method to detect IgE using a human Fc epsilon receptor (Fc?R) to detect IgE antibodies in a biological sample from a cat, a dog, or a horse. The present invention also relates to kits to perform such methods.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: March 27, 2007
    Assignee: Heska Corporation
    Inventors: Glenn R. Frank, James P. Porter, Keith E. Rushlow, Donald L. Wassom
  • Patent number: 7183080
    Abstract: The present invention relates to canine interleukin-5 proteins; canine interleukin-5 nucleic acid molecules, including those that encode canine interleukin-5 proteins; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: February 27, 2007
    Assignee: Heska Corporation
    Inventors: Shumin Yang, Catherine A. McCall, Eric R. Weber
  • Patent number: 7183386
    Abstract: The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; assays employing the transformed cells, nucleic acids, antibodies and/or proteins or portions thereof; methods for treating IgE-mediated responses (ie. allergy) using the materials provided; methods for eliciting an immune response to IgE and kits containing the nucleic acid molecules, proteins or derivatives thereof (ie. antibodies).
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: February 27, 2007
    Assignee: Heska Corporation
    Inventors: Catherine McCall, Eric Weber
  • Patent number: 7172873
    Abstract: The present invention provides a method for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested and (b) determining the amount of albumin in the sample. An amount of albumin in the range of from 10 ?g/ml to about 300 ?g/ml indicates the presence of early renal disease. The present invention also provides antibodies to canine, feline and equine albumin which can be used to detect the presence of early renal disease.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: February 6, 2007
    Assignee: Heska Corporation
    Inventors: Thomas McDonald, Wayne Arthur Jensen, Annika Weber, Janet S. Andrews
  • Patent number: 7169397
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 30, 2007
    Assignee: The University of Pittsburgh- of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7128921
    Abstract: The present invention relates to high molecular weight Dermatophagoides proteins, nucleic acid molecules encoding such proteins, and therapeutic and diagnostic reagents derived from such proteins.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: October 31, 2006
    Assignee: Heska Corporation
    Inventors: Catherine A. McCall, Shirley Wu Hunter, Eric R. Weber
  • Patent number: 7078506
    Abstract: The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF nucleic acid molecules, including those that encode canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins, respectively; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: July 18, 2006
    Assignee: Heska Corporation
    Inventors: Gek-Kee Sim, Shumin Yang, Matthew J. Dreitz, Ramani S. Wonderling
  • Patent number: 7074414
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: July 11, 2006
    Assignee: The University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7052899
    Abstract: The present invention relates to immunogenic Toxoplasma gondii proteins, to T. gondii nucleic acid molecules, including those that encode such proteins and to antibodies raised against such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules and antibodies. Also included in the present invention are compositions comprising such proteins, nucleic acid molecules and/or antibodies, as well as the use of such compositions to inhibit oocyst shedding by cats due to infection with T. gondii. The present invention also includes the use of certain T. gondii-based antisera to identify such nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins identified by such methods. The present invention also relates to novel methods for the detection of cysts and oocysts.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: May 30, 2006
    Assignee: Heska Corporation
    Inventor: Michael James Milhausen
  • Patent number: 7053181
    Abstract: The present invention relates to B7 proteins; to B7 nucleic acid molecules, including those that encode such B7 proteins; to antibodies raised against such B7 proteins; and to therapeutic compounds that regulate B7 function. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: May 30, 2006
    Assignee: Heska Corporation
    Inventors: Shumin Yang, Gek-Kee Sim
  • Patent number: 7041813
    Abstract: The present invention includes novel recombinant canine herpes virus (CHV) and novel recombinant CHV genomes, and particularly to those CHV and CHV genomes that contain heterologous nucleic acid molecules. The present invention also relates to the use of such genomes and viruses in a variety of applications, including as therapeutic compositions to protect animals from disease. The present invention also relates to novel isolated CHV nucleic acid molecules, to CHV proteins encoded by such nucleic acid molecules, and to antibodies raised against such CHV proteins as well as to the use of such CHV nucleic acid molecules, proteins and antibodies as therapeutic compositions to protect an animal from CHV. The present invention also includes constructs comprising CHV nucleic acid molecules that include heterologous nucleic acid molecules, to recombinant vectors including such constructs, and to the use of such constructs and vectors in the production of recombinant CHV and recombinant CHV genomes.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: May 9, 2006
    Assignee: Heska Corporation
    Inventors: Elizabeth J. Haanes, Rexann S. Frank
  • Patent number: 7029903
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus or other infectious agents utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: April 18, 2006
    Assignee: The University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7026139
    Abstract: The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF nucleic acid molecules, including those that encode canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins, respectively; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: April 11, 2006
    Assignee: Heska Corporation
    Inventor: Shumin Yang
  • Patent number: 6905682
    Abstract: The present invention relates to flea allantoinase proteins; to flea allantoinase nucleic acid molecules, including those that encode such flea allantoinase proteins; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit flea allantoinase activity, as well as the use of such therapeutic compositions to treat animals.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: June 14, 2005
    Assignee: Heska Corporation
    Inventors: Patrick J. Gaines, Nancy Wisnewski
  • Patent number: 6889145
    Abstract: The present invention includes three-dimensional models of antibodies, such as Fc-C?/C?4 regions of IgE antibodies, as well as methods to produce such models. The present invention also includes muteins having increased stability and/or antibody receptor binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of the model to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and other abnormal immune responses.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: May 3, 2005
    Assignee: Northwestern University
    Inventors: Theodore S. Jardetzky, Beth A. Wurzburg
  • Patent number: 6887672
    Abstract: The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: May 3, 2005
    Assignee: Heska Corporation
    Inventors: Eric R. Weber, Catherine A. McCall
  • Patent number: 6852847
    Abstract: The present invention relates to canine and feline B7 proteins; to B7 nucleic acid molecules, including those that encode such B7 proteins; to antibodies raised against such B7 proteins; and to therapeutic compounds that regulate B7 function. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: February 8, 2005
    Assignee: Heska Corporation
    Inventors: Gek-Kee Sim, Shumin Yang, Karen S. Sellins
  • Patent number: 6824784
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: November 30, 2004
    Assignee: The University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner